Latest News
Web Date: September 22, 2017

Metallopeptide catalyst eases synthesis of antibody-drug conjugates

A promising drug-targeting approach is made easier thanks to a new rhodium-based catalyst
Department: Science & Technology
News Channels: Biological SCENE, Organic SCENE, JACS In C&EN
Keywords: Biologics, antibody-drug conjugates, metallopeptide, drug development, rhodium, catalysts, Herceptin

Antibody-drug conjugates are promising next-generation cancer therapies that can target and selectively kill malignant cells while sparing healthy ones. These conjugates—in which a drug is bound to an antibody through a small chemical linker—harness the antibody’s ability to recognize markers specific to cancer cells and bring the potent drugs to their intended site of action. But one conundrum that has plagued drug developers and scientists is how to consistently tether a drug onto a predictable . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society